Skip to content
    Real-World Studies

    TP53 (Investigational) Y220C Prevalence, Survival Impact, and Genomic Landscape in Ovarian Cancer

    Nakajima et alJournal of gynecologic oncology

    TP53 (Investigational) Y220C Prevalence, Survival Impact, and Genomic Landscape in Ovarian Cancer
    In a nationwide retrospective study of 5,144 adult patients registered in the Japanese Center for Cancer Genomics and Advanced Therapeutics (C-CAT) database between June 2019 and May 2025, researchers evaluated the screening yield, prognostic relevance, and co-alteration landscape of the TP53 Y220C mutation in epithelial ovarian, fallopian tube, and primary peritoneal cancers. TP53 Y220C detection frequencies were assessed across histologic subtypes, and genomic co-alterations were evaluated among patients profiled with tissue-based FoundationOne CDx.
    The mutation was identified in 4.2% of high-grade serous carcinomas (HGSC; 96 of 2,278), 4.3% of endometrioid carcinomas (13 of 302), 1.8% of mucinous carcinomas (4 of 227), 1.0% of low-grade serous carcinomas (1 of 96), and 0.3% of clear cell carcinomas (3 of 962). In the HGSC subgroup, overall survival calculated from C-CAT registration showed an adjusted hazard ratio of 1.19 (95% confidence interval, 0.88–1.61; p=0.271) for Y220C versus non-Y220C tumors, with additional sensitivity analyses incorporating diagnosis-time-scale delayed-entry and pre-registration treatment-timing models.
    Furthermore, no individual gene or pathway-level co-alterations met the false discovery rate threshold. The study authors concluded that while neither survival outcomes nor co-alteration profiles reached statistical significance—with estimates remaining imprecise—the observed prevalence in approximately 4% of HGSC cases supports the utility of direct mutation-level detection through comprehensive genomic profiling.

    Key Takeaways

    • Across 5,144 screened patients, TP53 Y220C was detected in 4.2% of high-grade serous carcinomas (96/2,278), 4.3% of endometrioid carcinomas (13/302), 1.8% of mucinous carcinomas (4/227), 1.0% of low-grade serous carcinomas (1/96), and 0.3% of clear cell carcinomas (3/962).
    • In high-grade serous carcinoma, TP53 Y220C was not associated with a statistically significant difference in overall survival compared with non-Y220C tumors (adjusted hazard ratio, 1.19; 95% confidence interval, 0.88–1.61; p=0.271).
    • Tissue-based genomic profiling identified no pathway or individual gene co-alterations that met the false discovery rate threshold in TP53 Y220C-altered cases.
    Read the original sourceJournal of gynecologic oncology